Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biochemical models for cognition enhancers.

B Costall1, J M Barnes, M Hamon

  • 1Neuropharmacology Research Group, University of Bradford, England.

Pharmacopsychiatry
|February 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ethical Challenges in Clinical Research During the COVID-19 Pandemic.

Journal of bioethical inquiry·2020
Same author

Capture-recapture to estimate completeness of tuberculosis surveillance in two communities in South Africa.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2011
Same author

Accuracy and completeness of recording of confirmed tuberculosis in two South African communities.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2011
Same author

Traumatic oedema of larynx.

British dental journal·2010
Same author

Behavioural characterization of neuroleptic properties in the rodent.

Proceedings of the Royal Society of Medicine·2010
Same author

The Rationale of Complete Immobilization in Treatment of Infected Wounds.

British medical journal·2010

Investigating Alzheimer's disease, this study explores modulating the acetylcholine system. Serotonin (5-HT) and angiotensin converting enzyme (ACE) inhibitors show promise for enhancing memory function and cognition.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Gerontology

Background:

  • Alzheimer's disease (AD) is characterized by widespread brain dysfunction, with significant implications for the mesolimbic acetylcholine (ACh) system.
  • Understanding the complex etiology of AD is crucial for developing effective therapeutic strategies.

Purpose of the Study:

  • To evaluate novel therapeutic approaches for modulating acetylcholine (ACh) function in the context of Alzheimer's disease.
  • To assess the potential of somatostatin, serotonin (5-HT), and angiotensin II modulation for AD treatment.

Main Methods:

  • Review of existing literature on the roles of somatostatin, 5-HT, and angiotensin II in cholinergic function and cognition.
  • Analysis of correlations between neurochemical markers and receptor binding in relation to ACh activity.

Related Experiment Videos

  • Evaluation of preclinical and clinical evidence for cognitive enhancement and amnesia induction.

    • Main Results:

    • Modulating somatostatin is unlikely to be a viable therapeutic strategy for AD due to a lack of correlation with choline-acetyl-transferase activity.
    • Serotonin (5-HT) receptor modulation, particularly targeting 5HT1A receptors on cholinergic projections, shows potential for improving memory function.
    • Angiotensin converting enzyme (ACE) inhibitors demonstrate potential by facilitating ACh release and enhancing cognition, while piracetam may prevent age-related ACh receptor density decline.

    Conclusions:

    • Targeting the serotonin system and utilizing ACE inhibitors represent promising avenues for Alzheimer's disease therapeutics.
    • Further research into partial glutamate agonists and the complex mechanisms of ACh modulation is warranted.
    • Neuronal transplantation remains a challenging approach for AD due to global brain atrophy.